Effect of Low Dose Naloxone on the Immune System Function of a Patient Undergoing Video-assisted Thoracoscopic Resection of Lung Cancer with Sufentanil Controlled Analgesia - a Randomized Controlled Trial

Overview

Journal BMC Anesthesiol

Publisher Biomed Central

Specialty Anesthesiology

Date 2019 Dec 21

PMID 31856760

Citations 7

Authors

Yun Lin

Zhuang Miao

Yue Wu

Fang-Fang Ge

Qing-Ping Wen

Affiliations

Soon will be listed here.

Abstract

Background: Perioperative immune function plays an important role in the prognosis of patients. Several studies have indicated that low-dose opioid receptor blockers can improve immune function.

Methods: Sixty-nine patients undergoing video-assisted thoracoscopic resection of the lung cancer were randomly assigned to either the naloxone group (n = 35) or the non-naloxone group (n = 34) for postoperative analgesia during the first 48 h after the operation. Both groups received sufentanil and palonosetron via postoperative analgesia pump, while 0.05 μg·kg·h naloxone was added in naloxone group. The primary outcomes were the level of opioid growth factor (OGF) and immune function assessed by natural killer cells and CD4/CD8 T-cell ratio. Second outcomes were assessed by the intensity of postoperative pain, postoperative rescue analgesia dose, postoperative nausea and vomiting (PONV).

Results: The level of OGF in the naloxone group increased significantly at 24 h (p<0.001) and 48 h after the operation (P < 0.01). The natural killer cells (P < 0.05) and CD4/CD8 T-cell ratio (P < 0.01) in the naloxone group increased significantly at 48 h after the operation. The rest VAS scores were better with naloxone at 12 and 24 h after operation(P < 0.05), and the coughing VAS scores were better with naloxone at 48 h after the operation(P < 0.05). The consumption of postoperative rescue analgesics in the naloxone group was lower (0.00(0.00-0.00) vs 25.00(0.00-62.50)), P < 0.05). Postoperative nausea scores at 24 h after operation decreased in naloxone group(0.00 (0.00-0.00) vs 1.00 (0.00-2.00), P < 0.01).

Conclusion: Infusion of 0.05 μg·kg·h naloxone for patients undergoing sufentanil-controlled analgesia for postoperative pain can significantly increase the level of OGF, natural killer cells, and CD4+/CD8+ T-cell ratio compared with non-naloxone group, and postoperative pain intensity, request for rescue analgesics, and opioid-related side effects can also be reduced.

Trial Registration: The trial was registered at the Chinese Clinical Trial Registry on January 26, 2019 (ChiCTR1900021043).

Citing Articles

Opioids With or Without Low-Dose Naloxone During the Perioperative Period: A Systematic Review With Meta-Analysis.

Mao B, Wang X, Zhang X, Chen M Pain Res Manag. 2025; 2025:8380502.

PMID: 40027404 PMC: 11872289. DOI: 10.1155/prm/8380502.

Nanotechnology-Enhanced Naloxone and Alternative Treatments for Opioid Addiction.

Heyns I, Faunce A, Mumba M, Kumar M, Arora M ACS Pharmacol Transl Sci. 2024; 7(8):2237-2250.

PMID: 39144549 PMC: 11320732. DOI: 10.1021/acsptsci.4c00158.

Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial.

Min X, Ma Y, Leng Y, Li X, Zhang J, Xu S BMC Anesthesiol. 2024; 24(1):172.

PMID: 38720250 PMC: 11077871. DOI: 10.1186/s12871-024-02524-7.

Impact of opioids on postoperative prognosis in lung cancer.

Nakada T, Ohtsuka T J Thorac Dis. 2023; 15(10):5272-5274.

PMID: 37969287 PMC: 10636488. DOI: 10.21037/jtd-23-1223.

The effects of allogeneic and autologous blood transfusion on immune function in patients receiving total hip replacement.

Han Z, Li M, Zhang Y Am J Transl Res. 2023; 15(7):4709-4717.

PMID: 37560247 PMC: 10408532.

References

Plotnikoff N, Miller G, Nimeh N, Faith R, Murgo A, Wybran J . Enkephalins and T-cell enhancement in normal volunteers and cancer patients. Ann N Y Acad Sci. 1987; 496:608-19. DOI: 10.1111/j.1749-6632.1987.tb35821.x. View

Zagon I, Verderame M, McLaughlin P . The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002; 38(3):351-76. DOI: 10.1016/s0165-0173(01)00160-6. View

Jin S, Deng Y, Hao J, Li Y, Liu B, Yu Y . NK cell phenotypic modulation in lung cancer environment. PLoS One. 2014; 9(10):e109976. PMC: 4192363. DOI: 10.1371/journal.pone.0109976. View

Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

Yang C, Cherng C, Wu C, Huang H, Tao P, Lee S . Intrathecal ultra-low dose naloxone enhances the antihyperalgesic effects of morphine and attenuates tumor necrosis factor-α and tumor necrosis factor-α receptor 1 expression in the dorsal horn of rats with partial sciatic nerve transection. Anesth Analg. 2013; 117(6):1493-502. DOI: 10.1213/ANE.0000000000000020. View

Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F . Global cancer incidence in older adults, 2012 and 2035: A population-based study. Int J Cancer. 2018; 144(1):49-58. DOI: 10.1002/ijc.31664. View

Donahue R, McLaughlin P, Zagon I . The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol. 2011; 122(2):382-8. DOI: 10.1016/j.ygyno.2011.04.009. View

Dehghani M, Sharifpour S, Amirghofran Z, Zare H . Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients. Med Oncol. 2012; 29(4):2364-71. DOI: 10.1007/s12032-012-0176-1. View

McLaughlin P, Zagon I . The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. Biochem Pharmacol. 2012; 84(6):746-55. DOI: 10.1016/j.bcp.2012.05.018. View

10.

Sullivan R, Alatise O, Anderson B, Audisio R, Autier P, Aggarwal A . Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015; 16(11):1193-224. DOI: 10.1016/S1470-2045(15)00223-5. View

11.

Barrons R, Woods J . Low-Dose Naloxone for Prophylaxis of Postoperative Nausea and Vomiting: A Systematic Review and Meta-analysis. Pharmacotherapy. 2017; 37(5):546-554. DOI: 10.1002/phar.1930. View

12.

Molenaar I, Warnaar N, Groen H, TenVergert E, Slooff M, Porte R . Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2007; 7(1):185-94. DOI: 10.1111/j.1600-6143.2006.01591.x. View

13.

Boland J, McWilliams K, Ahmedzai S, Pockley A . Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer. 2014; 111(5):866-73. PMC: 4150281. DOI: 10.1038/bjc.2014.384. View

14.

Donahue R, McLaughlin P, Zagon I . Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011; 236(7):883-95. DOI: 10.1258/ebm.2011.011096. View

15.

Villegas F, Coca S, Villarrubia V, Jimenez R, Chillon M, Jareno J . Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2001; 35(1):23-8. DOI: 10.1016/s0169-5002(01)00292-6. View

16.

Wei G, Moss J, Yuan C . Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated?. Biochem Pharmacol. 2003; 65(11):1761-6. DOI: 10.1016/s0006-2952(03)00085-6. View

17.

Kowalski J . Immunologic action of [Met5]enkephalin fragments. Eur J Pharmacol. 1998; 347(1):95-9. DOI: 10.1016/s0014-2999(98)00079-x. View

18.

Ge Y, Lv R, Zhou W, Ma X, Zhong T, Duan M . Brain damage following severe acute normovolemic hemodilution in combination with controlled hypotension in rats. Acta Anaesthesiol Scand. 2007; 51(10):1331-7. DOI: 10.1111/j.1399-6576.2007.01448.x. View

19.

Aktas O, Ozturk A, Erman B, Erus S, Tanju S, Dilege S . Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018; 144(6):997-1003. DOI: 10.1007/s00432-018-2635-3. View

20.

Deniz G, Veen W, Akdis M . Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol. 2013; 132(3):527-535. DOI: 10.1016/j.jaci.2013.07.030. View